Literature DB >> 639435

Allopurinol kinetics.

K Hande, E Reed, B Chabner.   

Abstract

A spectrophotometric assay for measuring allopurinol and oxipurinol has been developed which can detect as little as 5 X 10(-8) M of each in serum and urine. With this assay, serum disappearance characteristics of intravenous and orally administered allopurinol have been investigated in man. Serum concentrations of both allopurinol and oxipurinol reach levels above 1 X 10(-5) M within minutes of intravenous administration and within 1 or 2 hr of oral administration of 300 mg allopurinol. Patients receiving 300 mg allopurinol daily show a mean serum concentration of 3 X 10(-5) M oxipurinol (range, 0.9 to 9 X 10(-5) M). Serum half-lives of allopurinol and oxipurinol were 39 +/- 11 min and 13.6 +/- 2.8 hr, respectively. Estimates of renal clearance were 13.6 and 18.9 ml/min for allopurinol and 23.2 and 30.6 ml/min for oxipurinol in 2 patients studied. The metabolic conversion of allopurinol to oxipurinol in man does not appear to be altered by long-term therapy with allopurinol, which suggests that this conversion takes place by way of an enzymatic reaction not strongly inhibited by either substrate or product. These results suggest the possibility of a nonxanthine oxidase enzymatic pathway for this conversion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 639435     DOI: 10.1002/cpt1978235598

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Use and abuse of allopurinol.

Authors:  J S Cameron; H A Simmonds
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

3.  Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

Authors:  R O Day; J O Miners; D J Birkett; A Whitehead; D Naidoo; J Hayes; E Savdie
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 4.  Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how.

Authors:  Nadiezhda Cantu-Medellin; Eric E Kelley
Journal:  Nitric Oxide       Date:  2013-02-27       Impact factor: 4.427

Review 5.  Clinical pharmacokinetics of allopurinol.

Authors:  G A Murrell; W G Rapeport
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

6.  Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; M Suda; K Higashino
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

7.  In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages.

Authors:  J D Berman; H K Webster
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

8.  Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.

Authors:  S J Appelbaum; M Mayersohn; R T Dorr; D Perrier
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

Authors:  B Breithaupt; M Tittel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.

Authors:  W Löffler; R Landthaler; J X de Vries; I Walter-Sack; A Ittensohn; A Voss; N Zöllner
Journal:  Clin Investig       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.